Celcuity (CELC)’s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View

Celcuity Inc. (NASDAQ:CELC) is among the hottest SMID-cap stocks so far in 2025. Following recent clinical progress, Wolfe Research initiated coverage on Celcuity on November 17, with an Outperform rating and a $110 price target, according to TheFly. Likoper/Shutterstock.com The firm highlighted the company’s strong momentum following the recent Phase 3 success for gedatolisib in second-line PIK3CA-WT breast cancer. With that success, it believes that the upcoming PIK3CA-mt readout should be a key catal ...